News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
16,518 Results
Type
Article (375)
Press Release (16143)
Section
Business (8802)
Career Advice (9)
Deals (1109)
Drug Delivery (1)
Drug Development (1937)
Employer Resources (1)
FDA (261)
Job Trends (392)
News (10935)
Policy (496)
Tag
Academia (33)
ADA (2)
Adcomms (1)
Allergies (5)
Alliances (324)
ALS (2)
Alzheimer's disease (35)
Antibody-drug conjugate (ADC) (26)
Approvals (304)
Artificial intelligence (11)
ASCO (9)
Autoimmune disease (14)
Bankruptcy (3)
Best Places to Work (375)
BIO (2)
Biosimilars (1)
BioSpace Insights (1)
Biotechnology (1)
Bladder cancer (4)
Brain cancer (4)
Breast cancer (22)
Cancer (205)
Cardiovascular disease (18)
Career advice (10)
Career pathing (1)
CAR-T (12)
Cell therapy (23)
Cervical cancer (3)
Clinical research (1906)
Collaboration (22)
Commercialization (1)
Compensation (23)
Complete response letters (2)
COVID-19 (42)
CRISPR (1)
C-suite (16)
Cystic fibrosis (1)
Data (318)
Depression (2)
Dermatology (3)
Diabetes (13)
Diagnostics (163)
Digital health (2)
Drug discovery (9)
Drug pricing (2)
Duchenne muscular dystrophy (21)
Earnings (9391)
Editorial (3)
Employer resources (1)
Events (1395)
Executive appointments (13)
FDA (464)
Friedreich's ataxia (1)
Frontotemporal dementia (3)
Funding (29)
Gene editing (4)
Gene therapy (7)
GLP-1 (30)
Government (39)
Guidances (111)
Healthcare (478)
Hematology (7)
HIV (1)
Huntington's disease (1)
IgA nephropathy (3)
Immunology and inflammation (8)
Indications (8)
Infectious disease (51)
Inflammatory bowel disease (2)
Influenza (7)
Intellectual property (5)
IPO (935)
Job creations (36)
Job search strategy (8)
JPM (1)
Labor market (3)
Layoffs (6)
Leadership (2)
Legal (98)
Liver cancer (3)
Longevity (1)
Lung cancer (35)
Lymphoma (29)
Manufacturing (17)
MASH (9)
Medical device (448)
Medtech (463)
Mergers & acquisitions (186)
Metabolic disorders (36)
mRNA (4)
Multiple sclerosis (2)
NASH (2)
Neurodegenerative disease (5)
Neuropsychiatric disorders (1)
Neuroscience (47)
NextGen: Class of 2026 (91)
Non-profit (46)
Obesity (14)
Opinion (1)
Ovarian cancer (2)
Pain (3)
Pancreatic cancer (10)
Parkinson's disease (7)
Patents (9)
Patient recruitment (16)
Peanut (3)
People (238)
Phase 1 (481)
Phase 2 (777)
Phase 3 (864)
Pipeline (886)
Postmarket research (75)
Preclinical (102)
Prostate cancer (11)
Radiopharmaceuticals (9)
Rare diseases (25)
Real estate (37)
Recruiting (1)
Regulatory (482)
Reports (3)
Research institute (31)
Rett syndrome (1)
RSV (1)
Schizophrenia (1)
Series A (5)
Series B (2)
Sickle cell disease (2)
Spinal muscular atrophy (2)
Startups (22)
Supply chain (2)
The Weekly (2)
Vaccines (20)
Venture capital (4)
Weight loss (13)
Women's health (4)
Worklife (1)
Date
Today (6)
Last 7 days (14)
Last 30 days (91)
Last 365 days (1209)
2026 (867)
2025 (1144)
2024 (1227)
2023 (1483)
2022 (1520)
2021 (1676)
2020 (1437)
2019 (983)
2018 (855)
2017 (721)
2016 (533)
2015 (683)
2014 (432)
2013 (209)
2012 (282)
2011 (334)
2010 (319)
Location
Africa (12)
Alabama (3)
Arizona (9)
Asia (1393)
Australia (71)
California (590)
Canada (140)
China (65)
Colorado (33)
Connecticut (24)
Delaware (20)
Europe (1971)
Florida (96)
Georgia (11)
Idaho (1)
Illinois (40)
Indiana (39)
Japan (15)
Kansas (2)
Kentucky (2)
Louisiana (6)
Maine (7)
Maryland (86)
Massachusetts (361)
Michigan (13)
Minnesota (24)
Missouri (14)
Montana (2)
Nevada (34)
New Hampshire (5)
New Jersey (142)
New York (130)
North Carolina (82)
Northern California (315)
Ohio (18)
Oklahoma (1)
Pennsylvania (120)
Rhode Island (1)
South America (16)
South Carolina (1)
Southern California (238)
Tennessee (4)
Texas (141)
United States (2055)
Utah (24)
Virginia (6)
Washington State (44)
Wisconsin (5)
16,518 Results for "106".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Inhibrx To Host Webcast Presentation to Provide Primary Endpoint Results for INBRX-106 Phase 2 First-Line HNSCC Study
September 6, 2026
·
2 min read
Press Releases
FDA Grants Fast Track Designation to SOTIO’s SOT106 ADC for Soft Tissue Sarcoma Treatment, Accelerating Clinical Development
August 26, 2026
·
3 min read
Press Releases
Inhibrx’s INBRX-106 Nearly Doubles Response Rate and Achieves Interim Median PFS of 9.6 months in Phase 2 HNSCC Study
September 8, 2026
·
10 min read
Press Releases
Rege Nephro Secures approximately US$10.6 Million to Advance RN-014 Toward Commercialization
July 21, 2026
·
4 min read
Approvals
GSK’s $10.6B Nuvalent bet pays off early as FDA approves lung cancer drug
Jideytro is GSK’s first approved product for lung cancer. With its takeover of Nuvalent Bio last month and a deal with Hansoh Pharmaceutical in 2023, the pharma now has several other lung cancer assets in late-stage development.
July 23, 2026
·
2 min read
·
Tristan Manalac
Mergers & acquisitions
GSK pays $10.6B for cancer biotech Nuvalent in industry’s second-biggest buy of the year
Nuvalent Bio is GSK’s third big-ticket purchase this year, after the pharma dropped $2.2 billion in January for RAPT Therapeutics and $950 million in February for 35Pharma.
June 9, 2026
·
2 min read
·
Tristan Manalac
Series A
Tortugas takes neuro deep dive with $106M to develop Eisai, Hansoh programs
With programs from Eisai and Hansoh Pharmaceutical in hand, Tortugas Neuroscience has emerged with hopes of delivering daily oral treatments to patients with central nervous system conditions.
April 21, 2026
·
1 min read
·
Gabrielle Masson
Press Releases
Antengene Announces Exclusive License Agreement with MPM BioImpact-Established K2 Therapeutics for ATG-106 and Option for Undisclosed Bispecific TCE
June 21, 2026
·
8 min read
Press Releases
SOTIO Receives U.S. FDA Orphan Drug Designation for SOT106, a Potential Best-in-Class ADC for Sarcoma
June 3, 2026
·
3 min read
Cancer
Inhibrx’s OX40 agonist add-on beats Keytruda alone in head and neck cancer
Inhibrx CEO Mark Lappe was particularly keen on INBRX-106’s performance in patients with HPV-positive disease and sees a nearly $4 billion near-term opportunity thanks to the Phase 2 results.
September 8, 2026
·
5 min read
·
Annalee Armstrong
1 of 1,652
Next
